Evidence map›Paper›PMID 28487897›Full record

SynthesisAfrican journal of traditional, complementary, and alternative medicines : AJTCAM2016

ASSOCIATION OF MTHFR A1298C POLYMORPHISM WITH BREAST CANCER AND/OR OVARIAN CANCER RISK: AN UPDATED META-ANALYSIS.

Wei Liu, Yi Li, Rui Li, Xiao Han, Ying Ma, Bin Liu, Xiangzhen Kong

Abstract readMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in African journal of traditional, complementary, and alternative medicines : AJTCAM, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Genes · 2021
    Review
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Wei LiuThe School of Nuclear Science and Technology Lanzhou University, School/Hospital of Stomatology Lanzhou University, Lanzhou City 730000, Gansu Province, China.
Yi LiThe co-first author, School of Basic Medical Sciences, Lanzhou University, Lanzhou City 730000, Gansu Province, China.
Rui LiLanzhou University School of Stomatology, Lanzhou City 730000, Gansu Province, China.
Xiao HanGansu University of Traditional Chinese Medicine, Lanzhou City 730000, Gansu Province, China.
Ying MaSchool of Basic Medical Sciences, Lanzhou University, Lanzhou City 730000, Gansu Province, China.
Bin LiuThe second corresponding author, the School of Nuclear Science and Technology Lanzhou University, School/hospital of Stomatology Lanzhou University, Lanzhou City 730000, Gansu Province, China.
Xiangzhen KongThe first corresponding author, Research Department, Qinghai University Affiliated Hospital, Xining City 810000, Qinghai Provincekongxzh12@aliyun.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundRecent years have witnessed the discovery of similar gene variations between breast cancer and ovarian cancer, inherited breast and ovarian cancer in particular. A large number of case-control studies have been conducted to explore the association of Methylenetetrahydrofolate Reductase (MTHFR) A1298C polymorphism with breast cancer and/or ovarian cancer risk. However, the results are still inconsistent and inconclusive. Consequently, we performed a meta-analysis to evaluate the association between MTHFR A1298C polymorphism and breast, ovarian cancer risk. MATERIALS AND

methodsA comprehensive retrieval was conducted in the electronic database of PubMed, Web of Science and Chinese National Knowledge Infrastructure (CNKI) until June 2015 to identify eligible studies. A total of 35 studies which examined the association of MTHFR A1298C polymorphism with breast cancer and/or ovarian cancer were identified. The pooled odds ratios (ORs) with 95 % confidence intervals (CIs) were used to assess the effect of gene polymorphism. And allele model, homozygous model, co-dominant model, dominant model, recessive model were applied.

resultIn the overall analysis, significantly increased breast cancer and/or ovarian cancer risk was found (for allele model A VS C OR = 1.05, CI: 1.02-1.08, P = 4χ10

conclusionIn the subgroup analysis, significantly increased breast cancer risk was identified among Caucasians. MTHFR A1298C polymorphism might contribute to an increased risk of breast cancer and/or ovarian cancer susceptibility. In addition, MTHFR A1298C polymorphism had a significant association with breast cancer in Caucasians.

Indexed as

Polymorphism, GeneticBreast NeoplasmsCase-Control StudiesFemaleGenetic Predisposition to DiseaseHumansMethylenetetrahydrofolate Reductase (NADPH2)Odds RatioOvarian NeoplasmsRisk FactorsMethylenetetrahydrofolate Reductase (NADPH2)MTHFR protein, humanBreast cancerMeta-analysisMTHFR A1298COvarian cancerPolymorphism

Identifiers

PMID28487897
PMCPMC5416649

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.